The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study

Ma, Qiang; Zhou, Yong; Ma, Baoan; Chen, Xiang; Yuan, Wen; Liu, Yunyan; Fan, Qingyu; Qiu, Xiuchun

doi:10.3892/ol.2012.558

Cited by 12 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the survival data of one article could not be used in this study. Finally, 6 [ 19 – 24 ] studies were included in this meta-analysis, which were published between1994 and 2014 (Figure 1 ). All of them were retrospective in design.…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of CD44 expression in osteosarcoma: evidence from six studies

Liu

et al. 2014

Diagn Pathol

View full text Add to dashboard Cite

BackgroundNumerous studies examining the relationship between CD44 expression and prognostic impact in patients with osteosarcoma have yielded inconclusive results. The aim of this meta-analysis was carried out to investigate the relationship between CD44 expression and the survival in patients with osteosarcoma.MethodsWe therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic role of CD44 expression on the overall survival rate and metastasis, which compared the positive and negative expression of CD44 in patients of the available studies.ResultsA detailed search was made in MEDLINE and EMBASE for relevant original articles published in English. Finally, a total of six studies with 329 osteosarcoma patients were involved to estimate the relationship between CD44 expression and metastasis of tumor and overall survival. Positive expressions of CD44 did not predict neoplasm metastasis (RR = 1.36, 95% CI: 1.00–1.84, P = 0.50), and the results indicated that higher expression of CD44 could not predict poorer survival in osteosarcoma with the pooled HR of 0.55 (95% CI: 0.27–1.13, P = 0.47).ConclusionsThe findings from this present meta-analysis suggest that CD44 expression is not associated with overall survival rate and metastasis in osteosarcoma.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1373995521295618

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic role of CD44 expression in osteosarcoma: evidence from six studies

Liu

et al. 2014

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…In this study, we evaluated the expression of the following genes: ErbB2, TGFβ, CD44, IL6, IL10, IL15, IL8, CD14, NF-kB/p65 (p65), IL18, TLR4, TLR5, TP53, MD2, MyD88, STAT5, iNOS, CXCR4, RAD51 and PTEN [13][14][15][16][17][18][19][20][21][22][23][24][25]. Genes selection has been made on the basis of their pivotal role in immune response to bacteria (CD44, IL6, IL8, CD14, p65, IL18, TLR4, TLR5, MD2, MyD88, STAT5, iNOS,) [26] or OSA development and metastasis (ErbB2, TGFβ, CD44, TP53, MD2, MyD88, STAT5, CXCR4, RAD51, IL8, IL6 and PTEN) [27][28][29][30][31][32].…”

Section: Gene Expression Analysismentioning

confidence: 99%

Characterization of D-17 Canine Osteosarcoma Cell Line and Evaluation of Its Ability to Response to Infective Stressor Used as Alternative Anticancer Therapy

Modesto

Fernandez²,

Martini

et al. 2020

Animals

View full text Add to dashboard Cite

Osteosarcoma (OSA) is a rare cancer both in human and dog although the incidence rate in dogs is 27 times higher than in human. Many studies employed D-17 as cell line for in vitro test to evaluate conventional anticancer therapies; however, little is known about D-17 cell line. The aim of our study was to evaluate the basal level of gene expression of pivotal molecules in the innate immune response and cell cycle regulation and to establish the ability of this cell line to react to Salmonella typhimurium (ST) infective stressor. IL15, IL10, iNOS, TLR5, CD14, PTEN and IL18 were expressed in an inconsistent manner among experiments. The other genes under study were expressed in all samples. ST showed ability to penetrate D-17 causing pro-inflammatory response. Our results outline the expression in D-17 of important genes involved in innate immune response. These results provide important data on D-17 basal gene expression profile useful for in vitro preliminary evaluation of new therapeutic approaches.

show abstract

“…This will improve the chances for successful clinical development of a potential product, as it is often more difficult to fund a costly development program when the patient population is limited. The tumor-associated antigens HER2 and EGFR are both known to be expressed in OS [ 9 , 10 ]. Marketed immunotherapeutic antibodies targeting these antigens (trastuzumab and cetuximab) are successful for treatment of other cancers, and could be of relevance for targeted therapy of OS [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma

et al. 2016

View full text Add to dashboard Cite

BackgroundOsteosarcoma is a rare form of cancer but with a substantial need for new active drugs. There is a particular need for targeted therapies to combat metastatic disease. One possible approach is to use an antibody drug conjugate or an antibody radionuclide conjugate to target the osteosarcoma metastases and circulating tumor cells. Herein we have evaluated a radiolabeled monoclonal antibody targeting CD146 both in vitro and in vivo.Methods and ResultsA murine monoclonal anti-CD146 IgG1 isotype antibody, named OI-3, was developed along with recombinant chimeric versions with human IgG1 or human IgG3 Fc sequences. Using flow cytometry, selective binding of OI-3 to human osteosarcoma cell lines OHS, KPDX and Saos-2 was confirmed. The results confirm a higher expression level of CD146 on human osteosarcoma cells than HER2 and EGFR; antigens targeted by commercially available therapeutic antibodies. The biodistribution of 125I-labeled OI-3 antibody variants was compared with 125I-labeled chimeric anti-EGFR antibody cetuximab in nude mice with subcutaneous OHS osteosarcoma xenografts. OI-3 was able to target CD146 expressing tumors in vivo and showed improved tumor to tissue targeting ratios compared with cetuximab. Subsequently, the three OI-3 variants were conjugated with p-SCN-Bn-DOTA and labeled with a more therapeutically relevant radionuclide, 177Lu, and their biodistributions were studied in the nude mouse model. The 177Lu-labeled OI-3 variants were stable and had therapeutically relevant biodistribution profiles. Dosimetry estimates showed higher absorbed radiation dose to tumor than all other tissues after administration of the chimeric IgG1 OI-3 variant.ConclusionOur results indicate that CD146 can be targeted in vivo by the radiolabeled OI-3 antibodies.

show abstract

The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study

Cited by 12 publications

References 15 publications

Prognostic role of CD44 expression in osteosarcoma: evidence from six studies

Prognostic role of CD44 expression in osteosarcoma: evidence from six studies

Characterization of D-17 Canine Osteosarcoma Cell Line and Evaluation of Its Ability to Response to Infective Stressor Used as Alternative Anticancer Therapy

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma

Contact Info

Product

Resources

About